CIMPASI-1: Certolizumab Pegol in Moderate to Severe Chronic Plaque Psoriasis

Phase 3, randomised, double-blind trial of certolizumab pegol in plaque psoriasis (3 arms), sponsored by UCB. Primary endpoints: Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at 16 weeks and Proportion of Subjects Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear Response at 16 weeks. Started Dec 2014; status: completed.